Editas Medicine, Inc. (EDIT)
收市後：
| 前收市價 | 8.00 |
| 開市 | 8.00 |
| 買盤 | 7.80 x 800 |
| 賣出價 | 8.05 x 800 |
| 今日波幅 | 7.74 - 8.11 |
| 52 週波幅 | 6.33 - 14.23 |
| 成交量 | |
| 平均成交量 | 1,373,124 |
| 市值 | 640.816M |
| Beta 值 (5 年，每月) | 1.79 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -2.97 |
| 業績公佈日 | 2023年10月31日 - 2023年11月06日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 13.13 |
Insider MonkeyEditas Medicine, Inc. (NASDAQ:EDIT) Q2 2023 Earnings Call Transcript
Editas Medicine, Inc. (NASDAQ:EDIT) Q2 2023 Earnings Call Transcript August 2, 2023 Editas Medicine, Inc. misses on earnings expectations. Reported EPS is $-0.78 EPS, expectations were $0.76. Operator: Good morning and welcome to Editas Medicine’s Second Quarter Conference Call. There will be a question-and-answer session at the end of this call. Please be advised that […]
Insider Monkey10 DNA Stocks Billionaires Are Loading Up On
In this article, we discuss 10 DNA stocks that billionaires love. If you want to skip our detailed analysis of the DNA market, head over to 5 DNA Stocks Billionaires Are Loading Up On. Genomics is the study of a complete set of DNA within an organism. The global genomics market was worth $28.39 billion […]
BenzingaEditas' Gene Editing Treatment Shows Initial Safety, Efficacy In Patients With Rare Blood Disorders
Editas Medicine Inc (NASDAQ: EDIT) announced initial safety and efficacy data from the first four patients with sickle cell disease (SCD) treated with EDIT-301 in the RUBY trial and from the first transfusion-dependent beta-thalassemia patient treated in the EdiTHAL trial. Patient 1’s total hemoglobin returned to a normal physiological level of 16.4g/dL at five months after infusion of EDIT-301 and has been maintained at this level at the 10-month follow-up. In addition, Patient 1’s fetal hemogl
